Iceland Genomics and Myriad form cancer gene deal:
This article was originally published in Clinica
Executive Summary
Biopharmaceutical firm Iceland Genomics has entered into cancer gene discovery collaboration with Myriad Genetics. Under the terms of the agreement, Myriad will supply genetic markers, which Reykjavik-based Iceland Genomics will use with its proprietary sample collection to help Myriad localise and identify a cancer gene. Iceland Genomics will receive research support and milestone payments and royalties on any diagnostic or therapeutic products that are developed by Myriad on the basis of the gene, said the firm. Financial details of the collaboration were not disclosed.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.